HIV/AIDS activists heralded the approval of a new twice-yearly pre-exposure prophylaxis (PrEP) medication last year, but ...

Providing pre-exposure prophylaxis (PrEP) medication to men who have sex with men who are at high risk of HIV infection (equivalent to less than 5% of men who have sex with men at any point in time) ...

The federal Food and Drug Administration October 3 approved a new daily PrEP pill that could offer a safer option for some individuals at risk for HIV, but the indication does not cover everyone who ...

Lenacapavir, a twice-yearly injectable antiretroviral, demonstrated 100% effectiveness for preventing HIV acquisition in a large study of young cisgender women in Africa, Gilead Sciences announced ...

The FDA has approved a new, twice-yearly PrEP injection from pharmaceutical giant Gilead. The drug is lenacapavir. The twice-yearly formulation has the brand name Yeztugo. Phase 3 trials showed that ...

Learning the best type of HIV prevention for those at highest risk can start with conversations about their options, writes Zandraetta Tims-Cook, MD, MPH, AAHIVS In the US, we have made remarkable ...

In this Oct. 7, 2019, file photo, a pharmacist displays the HIV prevention drugs Descovy, left and Truvada, right, at a pharmacy in Sacramento, Calif. A proposed federal policy aims to protect older ...